Elemental Impurities in Medical Devices: Risk Assessment

When Detection Doesn’t Equal Risk

A 2024 scientific study made headlines by detecting 16 metals or metalloids in tampon products. News coverage generated public concern about consumer safety, with some reports suggesting potential health risks from these detected elements.

But analytical chemistry teaches a fundamental lesson that often gets lost in public discourse: detection alone doesn’t determine risk. The critical question isn’t “are elements present?” but rather “do they leach at levels that matter during actual use?”

This distinction isn’t semantic. It represents the difference between total elemental composition (what’s in a product) and bioavailable exposure (what actually contacts the user). For medical devices and consumer products, this difference can be orders of magnitude.

How you extract and analyze samples fundamentally determines which question you’re answering and whether your conclusions reflect real-world safety or laboratory artifacts.

Watch: Extraction Method Comparison for Elemental Risk Assessment

In this video, Resolian scientist Nathan presents ICP-MS analysis of 28 elements in tampon products using three different extraction approaches, demonstrating how method selection profoundly affects both analytical results and risk interpretation.

Nathan’s work replicates and expands upon the 2024 study that generated public attention, but with a critical methodological comparison: acid digestion revealing total elemental content versus extraction conditions simulating actual product use. The results demonstrate why this distinction matters for accurate risk assessment.

What You’ll Learn in This Video:

  • The 2024 study findings that raised consumer safety questions
  • Why total elemental composition differs from bioavailable exposure
  • Three extraction approaches: acid digestion, exaggerated, and simulated-use
  • Why 20% ethanol simulates blood extracting power for medical device testing
  • ICP-MS detection of 28 elements across multiple product brands and absorbencies
  • How results vary dramatically by extraction method (10-100x differences)
  • ICH Q3D elemental limits and parenteral administration standards
  • Actual consumer risk assessment using simulated-use extraction
  • Why cobalt at under 6% of limit represents the highest detected percentage
  • The critical lesson: choosing extraction methods that answer the right risk question

Nathan’s comparative approach provides the context often missing from single-method studies: understanding what your analytical results actually mean for real-world exposure.

Understanding the Study Context

The study that prompted this investigation detected 16 metals or metalloids across various tampon brands and products. The findings were analytically valid and the detection itself wasn’t in question.

However, questions remained:

  • What extraction conditions were used?
  • Do the detected levels represent bioavailable exposure during normal use?
  • How do findings compare to established safety limits for similar exposures?
  • What do the numbers actually mean for consumer risk?

Nathan’s work addresses these questions by systematically comparing extraction approaches and contextualizing results against regulatory standards.

Download Poster

Download a copy of the poster discussed here.

The Three Extraction Approaches

Nathan designed a comparative study using three progressively less aggressive extraction methods:

  1. Microwave-Assisted Acid Digestion

    The most aggressive approach:
  • Cut up sample to maximize surface area
  • Concentrated acid (typically nitric acid)
  • Very high temperatures (up to 200°C) under pressure
  • Complete destruction of organic matrix

    What it reveals: Total elemental composition. Every element present in the product, regardless of whether it would leach during use.
    Advantage: Provides complete elemental profile useful for materials characterization and quality control.
    Limitation: Doesn’t represent user exposure. Products aren’t destroyed by concentrated acid at 200°C during normal use.
  1. Exaggerated Extraction
    Moderate aggression simulating worst-case conditions:
  • Whole sample (realistic physical form)
  • 20% ethanol solution
  • 50°C temperature (elevated but not extreme)
  • 3 days contact time (extended duration)

    What it reveals: Maximum plausible leaching under exaggerated but not unrealistic conditions.
    Why 20% ethanol? Previous studies demonstrated that 20% ethanol has similar extracting power to blood, making it physiologically relevant for medical devices that contact blood or bodily fluids. This makes it appropriate for simulating biological fluid extraction.
  1. Simulated-Use Extraction
    Realistic conditions matching actual product use:
  • Whole sample (as-used form)
  • 20% ethanol solution (blood-equivalent extracting power)
  • 37°C (body temperature)
  • 6 hours (typical maximum single-use duration)

    What it reveals: Bioavailable exposure under realistic use conditions. What actually leaches during normal product use.
    Why this matters most: This answers the consumer safety question. Not “what’s in the product” but “what does the user actually encounter?”

The Dramatic Results: 10-100x Differences

Nathan’s comparative analysis revealed stark differences in detected element concentrations depending on extraction method.

Acid digestion consistently produced the highest levels, frequently 10x higher than simulated-use extraction. For some elements, the difference reached 100x.

This isn’t measurement uncertainty or analytical error. It reflects the fundamental difference between total content (everything in the material) and extractable content (what leaches under specific conditions).

Interestingly, exaggerated extraction and simulated-use extraction produced similar results. This suggests that even the worst-case conditions (elevated temperature, extended duration) don’t dramatically increase extraction compared to realistic use conditions. The major determinant is whether you’re destroying the sample (acid digestion) or extracting under aqueous conditions (both extraction approaches).

ICH Q3D Context: Regulatory Standards for Elemental Impurities

To interpret whether detected levels matter, Nathan compared results to ICH Q3D elemental impurity limits. ICH Q3D provides risk-based limits for elemental impurities in pharmaceutical products based on:

  • Toxicological assessments
  • Route of administration
  • Daily exposure duration

The guideline categorizes elements by toxicity class and sets Permitted Daily Exposure (PDE) limits. These PDEs translate to concentration limits depending on daily dose.

Nathan used parenteral administration limits as the comparison standard. Parenteral (injectable) represents the most restrictive category because it bypasses first-pass metabolism and provides direct systemic exposure, similar to how tampon-leached elements would enter the bloodstream.

If detected levels are below parenteral limits, they’re below limits for all other routes of administration as well.

The Risk Assessment: Orders of Magnitude Below Limits

Using simulated-use extraction representing realistic consumer exposure:

All 24 ICH Q3D elements with established limits were detected at concentrations orders of magnitude less than the parenteral administration limit.

Even the highest detected element (cobalt) reached only 6% of the applicable limit. Most elements were detected at 1% of limit or less.

This means actual consumer exposure, measured under conditions simulating real use, is far below levels where regulatory concern begins.

Critically, these conservative findings use parenteral limits (the strictest standard) and simulated-use extraction (reflecting actual exposure). Even with these conservative assumptions, detected levels remain very low relative to safety thresholds.

Even Acid Digestion Shows Safe Levels

Importantly, even the most aggressive extraction approach (microwave acid digestion) that destroys the sample and reveals total elemental content still found all elements below ICH Q3D parenteral limits.

This means even in the worst-case scenario where somehow all elements in the product became bioavailable (which doesn’t reflect reality), levels would still be below regulatory thresholds.

The Critical Lesson: Extraction Method Determines Risk Conclusions

Nathan’s comparative study demonstrates a principle with broad implications beyond this specific application:

Total elemental composition data can be useful for manufacturers needing to understand materials or monitor batch consistency. It answers “what’s in this product?”

But it doesn’t accurately represent consumer risk when the product isn’t being destroyed during use. Users don’t ingest concentrated acid at 200°C. They use products under body temperature, aqueous conditions, for limited durations.

Simulated-use extraction designed to represent actual use conditions provides realistic risk assessment. It answers “what does the user actually encounter?”

This distinction applies across medical devices, consumer products, and any application where extraction conditions should match exposure conditions.

Broader Applications: When Method Selection Changes Everything

Nathan’s investigation focused on tampon products, but the principles extend broadly:

  • Medical devices: Choosing extraction conditions that simulate blood contact, tissue contact, or specific use durations
  • Consumer products: Selecting conditions matching actual use (handling, wearing, environmental exposure)
  • Pharmaceutical packaging: Simulating drug product contact conditions rather than worst-case destruction
  • Food contact materials: Matching food types, temperatures, and contact times
  • Environmental samples: Considering bioavailability versus total content

In each application, the question “what extraction method should I use?” directly determines whether results inform real-world risk or provide technically accurate but misleading information.

Quality Science Requires Asking the Right Question

Headlines announcing “metals detected in consumer products” generate attention but may not inform safety understanding. The quality of risk assessment depends on:

  • Designing extraction conditions matching actual exposure
  • Comparing results to appropriate regulatory standards
  • Distinguishing total content from bioavailable exposure
  • Communicating what results actually mean for safety

Nathan’s work exemplifies this approach: replicate the concerning study, add methodological rigor through comparison, contextualize against regulatory standards, and communicate findings that actually inform risk rather than generate unwarranted alarm or false reassurance.

Expert Elemental Analysis and Risk Assessment

Resolian’s analytical sciences team brings comprehensive capabilities for elemental impurity testing and risk assessment:

  • ICP-MS analysis for 28+ elements at trace levels
  • Multiple extraction approaches: acid digestion, exaggerated, simulated-use
  • ICH Q3D compliance testing and interpretation
  • Method development matching specific use conditions
  • Medical device and consumer product testing
  • Risk assessment contextualization against regulatory standards

Whether you need elemental analysis for quality control, regulatory submission, or safety assessment, we bring the methodology expertise to design extraction protocols that answer the questions that matter for your application.

Ready to discuss elemental impurity testing or extraction method development?

Contact our analytical sciences team to explore how proper method selection delivers results that accurately reflect real-world risk.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.